Shots:

• Gilead collaborates with Eisai to distribute & co-promote filgotinib for RA. Gilead will be accountable for manufacturing and approval of filgotinib while Eisai will be responsible for distribution in Japan for RA and other future indications
• Following the approval- the companies will jointly commercialize filgotinib. The agreement will extend to additional potential indications for filgotinib including UC- CD and PsA
• Filgotinib is an investigational- oral- selective JAK1 inhibitor with its pending approval for RA in Japan- currently being evaluated in P-III SELECTION- DIVERSITY- PENGUIN study for UC- CD- PsA and P-II studies for uveitis & in the small bowel and fistulizing CD respectively

Click here ­to­ read full press release/ article 

Ref: Gilead | Image: Gilead